RESUMO
Resumen Caso clínico: paciente de 73 años de edad, con diagnóstico de adenocarcinoma ductal infiltrante en la mama izquierda. Se trató con mastectomía total, linfadenectomía axilar y quimioterapia. Diez años después le aparecieron un linfedema en el brazo izquierdo y hombro congelado. El linfedema estaba muy indurado y eritematoso, con numerosas lesiones costrosas y sobreinfectadas. La biopsia cutánea mostró infiltración neoplásica debida al carcinoma mamario y reporte de aumento de Ca 15.3. En el escáner cérvico-tóraco-abdomino-pélvico se observó derrame pleural izquierdo masivo, con atelectasia pulmonar subyacente y múltiples erosiones óseas, compatible con afectación tumoral. Tras recibir quimioterapia paliativa disminuyó temporalmente la infiltración cutánea tumoral. Conclusión: el carcinoma mamario es uno de principales cánceres que afectan a la mujer. Sus metástasis cutáneas son del orden de 37% a 5 años. El carcinoma en coraza es una variedad excepcional (3%), de evolución lenta, sin daño sistémico. Las pacientes con cáncer de mama deben tener un seguimiento estrecho postmastectomía y ante la sospecha de metástasis cutánea, diagnosticarla oportunamente para ofrecerles la opción del tratamiento temprano.
Abstract Clinical case: patient of 73 years of age, with diagnosis of infiltrating ductal adenocarcinoma in the left breast in 2004; it was treated with total mastectomy, axillary lymphadenectomy and chemotherapy; 10 years later, she had induration and erythema in the mastectomy area, with some superficial necrotic lesions and cutaneous infiltration to the right breast. In the left arm: indurated lymphedema, with numerous crusted, superficial and superinfected lesions. The skin biopsy showed neoplastic infiltration due to mammary carcinoma and an increase in Ca 15.3. In the cervico-thoraco-abdominal-pelvic scan, massive left pleural effusion was observed, with underlying pulmonary atelectasis and multiple bone erosions, compatible with tumor involvement. After receiving palliative chemotherapy, the cutaneous infiltration of the tumor decreased temporarily. Conclusion: mammary carcinoma is one of the main cancers that affect women. Their cutaneous metastases are of the order of 37% at 5 years. Cutaneous carcinoma is an exceptional variety (3%), of slow evolution, without systemic damage. Patients with breast cancer should have a close postmastectomy follow-up and, in case of skin metastasis suspicion, diagnose it in a timely manner to offer them the option of early treatment.
RESUMO
Cardiac metastases are more frequent than primary heart neoplasias. Nearly any malignant tumour may metastasize to the heart, but the most common are carcinomas rather than sarcomas. We report the case of a patient who presented with heart metastasis 6 years after resection of an uterine leiomyosarcoma. The patient died thirty months after surgical resection without evidence of cardiac recurrence. Although cardiac metastases from uterine leiomyosarcoma are exceptional, they should be suspected in the presence of suggestive symptoms, since they can be associated with long survival after surgical treatment.
Assuntos
Neoplasias Cardíacas/secundário , Leiomiossarcoma/secundário , Neoplasias Uterinas/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Dacarbazina/administração & dosagem , Dacarbazina/análogos & derivados , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Erros de Diagnóstico , Docetaxel , Doxorrubicina/administração & dosagem , Evolução Fatal , Feminino , Neoplasias Cardíacas/cirurgia , Humanos , Histerectomia , Ifosfamida/administração & dosagem , Neoplasias Renais/tratamento farmacológico , Neoplasias Renais/secundário , Neoplasias Renais/cirurgia , Leiomioma/diagnóstico , Leiomiossarcoma/diagnóstico , Leiomiossarcoma/tratamento farmacológico , Leiomiossarcoma/cirurgia , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/cirurgia , Pessoa de Meia-Idade , Ovariectomia , Taxoides/administração & dosagem , Temozolomida , Cirurgia Torácica Vídeoassistida , Neoplasias Uterinas/diagnóstico , Neoplasias Uterinas/cirurgia , GencitabinaRESUMO
Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for cardiovascular disease. The aim of this trial was to evaluate the efficacy and safety of once-daily atorvastatin 10-80 mg for the treatment of hyperlipidemia in type 2 diabetics with plasma low-density lipoprotein cholesterol (LDL-C) levels exceeding 3.4 mmol/l (130 mg/dl). One hundred and two patients met the study criteria and received 10 mg/day atorvastatin. Patients who reached the target LDL-C level of
Assuntos
Anticolesterolemiantes/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Ácidos Heptanoicos/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Pirróis/uso terapêutico , Anticolesterolemiantes/efeitos adversos , Atorvastatina , Feminino , Ácidos Heptanoicos/efeitos adversos , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Hiperlipidemias/sangue , Hiperlipidemias/complicações , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Pirróis/efeitos adversosRESUMO
OBJECTIVE: To evaluate the fibrinogen and lipids response to diet plus bezafibrate in insulin-resistant patients with arterial hypertension and mixed hyperlipidemia. METHODS: A randomized double blind parallel design was used during a 90 days treatment period. Fibrinogen, lipids, insulin and peptide C assays as well as a glucose tolerance test were done at the start and end of treatment. The 28 patients received a hypolipemic diet low in refined sugars with bezafibrate added (400 mg/day) in 15 and a placebo in 13. RESULTS: The groups were similar in age, blood pressure and BMI. At the end of treatment, fibrinogen, cholesterol, triglycerides and LDL-C were lower in both groups as compared to the initial values, but only in the bezafibrate group there were: a) significant decrease in triglycerides (64 mg/dL, p 0.01); and b) marginal changes in fibrinogen (decreased 35 mg/dL, p = 0.09), total cholesterol (decreased 26 mg/dL, p = 0.10) and glucose/insulin ratio (increased from 4.4 to 5.2, p = 0.09). Bezafibrate lowered slightly the insulin level but did not affect peptide C. A correlation of changes in fibrinogen levels and the 60 min insulin concentration in the glucose tolerance test was higher in the bezafibrate group (r = 0.61) than in the placebo group (r = 0.23). CONCLUSIONS: In insulin resistant patients with high cardiovascular risk, bezafibrate and a placebo added to a hypolipemic diet decreased plasma fibrinogen. Bezafibrate lowered significantly the levels of triglycerides in these patients.